Literature DB >> 26595082

Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes.

K Yakushijin1, Y Atsuta2,3, N Doki4, A Yokota5, H Kanamori6, T Miyamoto7, C Ohwada8, K Miyamura9, Y Nawa10, M Kurokawa11, I Mizuno12, T Mori13, M Onizuka14, J Taguchi15, T Ichinohe16, H Yabe17, Y Morishima18, K Kato19, R Suzuki20, T Fukuda21.   

Abstract

This retrospective study was conducted in Japan to determine the incidence, risk factors and outcomes of sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic stem cell transplantation (HSCT). Among 4290 patients undergoing allogeneic HSCT between 1999 and 2010, 462 were diagnosed with SOS according to the Seattle criteria (cumulative incidence, 10.8%). The cumulative incidence of SOS diagnosed by the modified Seattle criteria was 9.3%. Of 462 patients, 107 met the Baltimore criteria and 168 had severe SOS with renal and/or respiratory failure. The median onset for SOS was 12 days after HSCT (range, -2-30). Overall survival at day 100 was 32% for SOS and 15% for severe SOS. Multivariate analyses showed that significant independent risk factors for SOS were the number of HSCTs, age, performance status, hepatitis C virus-seropositivity, advanced disease status and myeloablative regimen. SOS was highly associated with overall mortality (hazard ratio, 2.09; P<0.001). Our retrospective survey showed that the cumulative incidence of SOS in Japan was 10.8%, similar to that previously reported in Western countries, and that the overall survival of patients who developed SOS was low. Furthermore, several risk factors were identified. Preventive and therapeutic strategies for high-risk SOS patients must be established to improve overall survival.

Entities:  

Mesh:

Year:  2015        PMID: 26595082     DOI: 10.1038/bmt.2015.283

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  37 in total

1.  Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.

Authors:  R Chopra; J D Eaton; A Grassi; M Potter; B Shaw; C Salat; P Neumeister; G Finazzi; M Iacobelli; K Bowyer; H G Prentice; T Barbui
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

2.  Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post allogeneic hematopoietic SCT.

Authors:  D Nakamura; M Yoshimitsu; H Kawada; H Inoue; T Kuroki; T Kaieda; S Fujino; H Hamada; S Suzuki; K Matsushita; K Uozumi; N Arima
Journal:  Bone Marrow Transplant       Date:  2011-05-09       Impact factor: 5.483

3.  The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.

Authors:  Enric Carreras; Marina Díaz-Beyá; Laura Rosiñol; Carmen Martínez; Francesc Fernández-Avilés; Montserrat Rovira
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-25       Impact factor: 5.742

Review 4.  How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation.

Authors:  Enric Carreras
Journal:  Br J Haematol       Date:  2014-11-17       Impact factor: 6.998

5.  Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study.

Authors:  Mats Remberger; Malin Ackefors; Sofia Berglund; Ola Blennow; Göran Dahllöf; Aldona Dlugosz; Karin Garming-Legert; Jens Gertow; Britt Gustafsson; Moustapha Hassan; Zuzana Hassan; Dan Hauzenberger; Hans Hägglund; Helen Karlsson; Lena Klingspor; Gunilla Kumlien; Katarina Le Blanc; Per Ljungman; Maciej Machaczka; Karl-Johan Malmberg; Hanns-Ulrich Marschall; Jonas Mattsson; Richard Olsson; Brigitta Omazic; Darius Sairafi; Marie Schaffer; Britt-Marie Svahn; Petter Svenberg; Lisa Swartling; Attila Szakos; Michael Uhlin; Mehmet Uzunel; Emma Watz; Annika Wernerson; Agneta Wikman; Ann-Charlotte Wikström; Jacek Winiarski; Olle Ringdén
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

6.  Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.

Authors:  June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steve M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis J Giles
Journal:  Leuk Res       Date:  2006-09-07       Impact factor: 3.156

7.  Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.

Authors:  G B McDonald; P Sharma; D E Matthews; H M Shulman; E D Thomas
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

8.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

9.  BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.

Authors:  Fiona L Dignan; Robert F Wynn; Nedim Hadzic; John Karani; Alberto Quaglia; Antonio Pagliuca; Paul Veys; Michael N Potter
Journal:  Br J Haematol       Date:  2013-09-17       Impact factor: 6.998

10.  How I treat sinusoidal obstruction syndrome.

Authors:  Nelson Chao
Journal:  Blood       Date:  2014-05-15       Impact factor: 22.113

View more
  16 in total

Review 1.  Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation.

Authors:  Mitchell S Cairo; Kenneth R Cooke; Hillard M Lazarus; Nelson Chao
Journal:  Br J Haematol       Date:  2020-03-04       Impact factor: 6.998

2.  Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo".

Authors:  Stefano Botti; Iris Agreiter; Laura Orlando; Gianpaolo Gargiulo; Francesca Bonifazi; Marina Marialuisa Banfi; Lorella Cappucciati; Cristiana Caffarri; Valentina De Cecco; Giuseppe Marco Deiana; Marta Gavezzotti; Antonio Magarò; Maria Giovanna Netti; Adriana Concetta Pignatelli; Elena Rostagno; Emanuela Samarani; Janini Silva Cardoso; Sonia Soave; Concetta Maria Valente; Alessio Vedovetto; Marco Zecca; Stefano Luminari; Francesco Merli; Monica Guberti
Journal:  Support Care Cancer       Date:  2020-02-13       Impact factor: 3.603

Review 3.  The oncologic burden of hepatitis C virus infection: A clinical perspective.

Authors:  Harrys A Torres; Terri Lynn Shigle; Nassim Hammoudi; James T Link; Felipe Samaniego; Ahmed Kaseb; Vincent Mallet
Journal:  CA Cancer J Clin       Date:  2017-07-06       Impact factor: 508.702

Review 4.  Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.

Authors:  Paul G Richardson; Stephan A Grupp; Antonio Pagliuca; Amrita Krishnan; Vincent T Ho; Selim Corbacioglu
Journal:  Int J Hematol Oncol       Date:  2017-08-11

5.  Defibrotide-treated patients with anicteric or icteric veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study.

Authors:  Mohamad Mohty; Thomas Cluzeau; Charlotte Jubert; Sarah Lawson; Robert J Ryan; Raj Hanvesakul; Katia Perruccio
Journal:  Bone Marrow Transplant       Date:  2022-02-03       Impact factor: 5.483

6.  Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.

Authors:  S Corbacioglu; E Carreras; M Ansari; A Balduzzi; S Cesaro; J-H Dalle; F Dignan; B Gibson; T Guengoer; B Gruhn; A Lankester; F Locatelli; A Pagliuca; C Peters; P G Richardson; A S Schulz; P Sedlacek; J Stein; K-W Sykora; J Toporski; E Trigoso; K Vetteranta; J Wachowiak; E Wallhult; R Wynn; I Yaniv; A Yesilipek; M Mohty; P Bader
Journal:  Bone Marrow Transplant       Date:  2017-07-31       Impact factor: 5.483

7.  Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant.

Authors:  Zheng-Yi Zhou; Wenxi Tang; Kathleen F Villa
Journal:  Clinicoecon Outcomes Res       Date:  2018-12-17

Review 8.  Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.

Authors:  Xiao-Qian Yang; Jin Ye; Xin Li; Qian Li; Yu-Hu Song
Journal:  World J Gastroenterol       Date:  2019-07-28       Impact factor: 5.742

9.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.

Authors:  M Mohty; F Malard; M Abecassis; E Aerts; A S Alaskar; M Aljurf; M Arat; P Bader; F Baron; A Bazarbachi; D Blaise; F Ciceri; S Corbacioglu; J-H Dalle; F Dignan; T Fukuda; A Huynh; T Masszi; M Michallet; A Nagler; M NiChonghaile; S Okamoto; A Pagliuca; C Peters; F B Petersen; P G Richardson; T Ruutu; B N Savani; E Wallhult; I Yakoub-Agha; R F Duarte; E Carreras
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

10.  Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Authors:  Nancy A Kernan; Stephan Grupp; Angela R Smith; Sally Arai; Brandon Triplett; Joseph H Antin; Leslie Lehmann; Tsiporah Shore; Vincent T Ho; Nancy Bunin; Massimo Iacobelli; Wei Liang; Robin Hume; William Tappe; Robert Soiffer; Paul Richardson
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.